InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,317.60
(
0.94%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.97
(
0.81%
)
Bitcoin
68,920.71
(
1.47%
)
Post# of 260
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mick

Send PM Follow Ignore
Followers 3155
Posts 961472
Boards Moderated 180
Alias Born 09/04/2000

mick

Member Level

Re: mick post# 121

Wednesday, 12/21/2005 11:20:16 PM

Wednesday, December 21, 2005 11:20:16 PM

Post# of 260
Pfizer's Varenicline receives U.S. FDA priority review (PFE) 24.26 +0.26:Co announces the FDA has granted a six-month priority review for the New Drug Application for the co's smoking cessation medicine, varenicline tartrate, which the co intends to market under the brand name Champix. The FDA assigns priority review status to medicines that may provide a significant therapeutic advance over existing therapies.



Caspermick

"TOUGH TIMES NEVER LAST BUT TOUGH PEOPLE DO."


God Bless America

In Gambling,,,Playing Card Games. Ya Never Know What The Next Hand Will Look Like.
Ten Bagger Potential Stock

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up